Effects of Cervical Manual Therapy for Temporomandibular Disorders With Myalgia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: upper cervical mobilization, placebo maneuver.
- Who it may be relevant to
- Registry conditions: Temporomandibular Disorders (TMDs). Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Background: Temporomandibular disorders (TMDs) are the leading cause of non-odontogenic orofacial pain interfering with daily activities. TMDs consist of a group of conditions affecting the masticatory muscles, the temporomandibular joint (TMJ), or the associated structures. Previous studies showed alterations in TMJ kinematics, cortical excitability, electromyographic (EMG) activity of the masticatory muscles, and tongue pressure in individuals with TMDs compared to healthy controls. Furthermore, several studies have demonstrated that manual therapy applied to the cervical joint could reduce pain and improve jaw function in individuals with TMDs. However, the effects of upper cervical mobilization on TMJ kinematics, cortical excitability, tongue pressure, and EMG of masticatory muscles during mouth opening in individuals with myogenous TMDs remain unknown. Purpose: This study aims to investigate the immediate effects of upper cervical mobilization on TMJ kinematics, EMG of masticatory system muscles, cortical excitability, and tongue pressure in individuals with myogenous TMDs. Methods: A randomized controlled trial will be conducted with a total sample size of 48 participants. Individuals diagnosed with myogenous TMDs, defined as chronic myalgia (lasting \>3 months continuously or \> 6 months intermittently) according to the Diagnostic Criteria for Temporomandibular Disorders, will be recruited for this study. Participants will be randomly assigned to either the experimental or the control group, stratified by age and sex. The experimental group will receive a single session of upper cervical mobilization, while the control group will receive a placebo maneuver. The primary outcomes will include TMJ kinematics and EMG activity of the masseter and suprahyoid muscles, while the secondary outcomes will include cortical excitability, tongue pressure, pain intensity, and upper cervical mobility. All measurements will be taken before and immediately after the intervention. Statistical analysis: The continuous and categorical variables of clinical and demographic characteristics will be analyzed by an independent t test/Mann-Whitney U test and a Chi-square test, respectively. A 2×2 mixed-model analysis of variance (ANOVA) will be used to analyze the outcome measures and to test the main effects and interactions between time and group. If there is a significant interaction effect, post hoc pairwise comparisons with Bonferroni correction will be used. The alpha level is set at 0.05.
Interventions
- Other upper cervical mobilization
Upper cervical mobilization will focus on the atlanto-axial joint. All techniques will adhere to the International Federation of Orthopaedic Manipulative Physical Therapists (IFOMPT) guidelines to minimize the risk of adverse effects 75. Participants will remain in a supine position with their head in a neutral alignment. The physical therapist will apply translatoric mobilization, aligning the transverse process of the atlas (C1) as closely as possible with the transverse process of the axis (C - Other placebo maneuver
Participants will also remain in a supine position with a neutral head posture. However, instead of performing mobilization, the physical therapist will simply place their hands on C1 and C2 without applying any force.
Primary outcome measures
- Range of maximum mouth opening as assessed by Zebris Jaw Motion Analyzer device [Time frame: Before and immediately after the intervention]
- Range of mandibular protrusion as assessed by Zebris Jaw Motion Analyzer device [Time frame: Before and immediately after the intervention]
- Range of mandibular lateral excursion as assessed by Zebris Jaw Motion Analyzer device [Time frame: Before and immediately after the intervention]
- Condylar path length as assessed by Zebris Jaw Motion Analyzer device [Time frame: Before and immediately after the intervention]
- Condylar rotation as assessed by Zebris Jaw Motion Analyzer device [Time frame: Before and immediately after the intervention]
- Condylar translation as assessed by Zebris Jaw Motion Analyzer device [Time frame: Before and immediately after the intervention]
- Activation of masseter muscles as assessed by surface electromyography (sEMG) (BIOPAC MP150 system) [Time frame: Before and immediately after the intervention]
- Activation of suprahyoid muscles as assessed by surface electromyography (sEMG) (BIOPAC MP150 system) [Time frame: Before and immediately after the intervention]
Secondary outcome measures (4)
- Cortical excitability of M1 as assessed by Magstim transcranial magnetic stimulator [Time frame: Before and immediately after the intervention]
- Maximum tongue pressure values as assessed by wireless tongue pressure measurement device (OCPT-168, Shi-Heng Technology Co. Ltd., Taiwan) [Time frame: Before and immediately after the intervention]
- Self reported masticatory muscle pain intensity as assessed by Visual Analog Scale [Time frame: Before and immediately after the intervention]
- Upper cervical mobility as assessed by flexion-rotation test at atlanto-axial level [Time frame: Before and immediately after the intervention]
Eligibility criteria
Inclusion criteria
- Diagnosed with myogenous TMDs, defined as chronic myalgia (lasting >3 months continuously or > 6 months intermittently) 90 with or without accompanying arthralgia according to DC/TMD criteria
- A visual analogue scale (VAS) score of 3 or greater at baseline
- 18 to 60 years of age
Exclusion criteria
- Diagnosed with disc displacement without reduction or degenerative joint disease according to the DC/TMD criteria
- A diagnosis of systemic diseases such as fibromyalgia, rheumatoid arthritis, systemic erythematous lupus, or psoriatic arthritis
- A diagnosis of neurological disorders (e.g., trigeminal neuralgia, cervical radiculopathy, or myelopathy)
- Evidence of central nervous system involvement (positive pathological reflexes)
- A history of traumatic injuries (e.g., contusion, fracture, or whiplash injury) in the last 6 weeks
- Signs of vertebral artery insufficiency or upper cervical instability revealed by physical examination
- Receiving cervical spine mobilization or manipulation or acupuncture for their TMDs within the last 1 week
- any contraindication to TMS
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07647887 · NYCU114159AF